Evidence map›Paper›PMID 29559125›Full record

ArticleTuberculosis (Edinburgh, Scotland)2018

Evaluation of a synthetic peptide for the detection of anti-Mycobacterium tuberculosis curli pili IgG antibodies in patients with pulmonary tuberculosis.

Natasha Naidoo, Balakrishna Pillay, Martin Bubb, Alexander Pym, Thamsanqa Chiliza, Kogieleum Naidoo, Thumbi Ndung'u, Victoria O Kasprowicz, Manormoney Pillay

Abstract readEvaluation Study
In one paragraph

Article in Tuberculosis (Edinburgh, Scotland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. In silico design ofHeliyon · 2024
    Article
  4. A systematic review of potential screening biomarkers for active TB disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2021
    Review
  5. Article
  6. Article
  7. Lectins ofBeilstein journal of organic chemistry · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Natasha NaidooMedical Microbiology, University of KwaZulu-Natal, South Africa.
Balakrishna PillayDiscipline of Microbiology, University of KwaZulu-Natal, South Africa.
Martin BubbNational Bioproducts Institute, South Africa.
Alexander PymAfrica Health Research Institute, University of KwaZulu-Natal, South Africa.
Thamsanqa ChilizaDiscipline of Microbiology, University of KwaZulu-Natal, South Africa.
Kogieleum NaidooSouth African Medical Research Council HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.
Thumbi Ndung'uAfrica Health Research Institute, University of KwaZulu-Natal, South Africa; Ragon Institute of MGH, MIT and Harvard, USA; HIV Pathogenesis Programme, University of KwaZulu-Natal, South Africa; Max Planck Institute for Infection Biology, Germany.
Victoria O KasprowiczAfrica Health Research Institute, University of KwaZulu-Natal, South Africa; HIV Pathogenesis Programme, University of KwaZulu-Natal, South Africa.
Manormoney PillayMedical Microbiology, University of KwaZulu-Natal, South Africa. Electronic address: pillayc@ukzn.ac.za.
University of KwaZulu-Natal · ZAAfrica Health Research Institute · ZANational Bioproducts Institute (South Africa) · ZARagon Institute of MGH, MIT and Harvard · USSouth African Medical Research Council · ZA

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
The Viral Set Point in HIV-1 Subtype C InfectionU19AI051794 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI ABDOOL KARIM, SALIM S · 2002 to 2007
$22.5M
NIAID NIH HHS P30 AI060354NIAID NIH HHS U19 AI051794Wellcome TrustWellcome Trust 107752/Z/15/Z
6 · The paper itself

Abstract

Tuberculosis (TB) remains a serious threat in underdeveloped areas. Mycobacterium tuberculosis curli pili (MTP), a virulence factor, is a potential biomarker for a reliable point of care (POC) test and was evaluated for its ability to react with Immunoglobulin G (IgG) in TB patients. An MTP synthetic peptide in a slot blot assay was used to screen serum/plasma samples (n = 65) in 3 separate cohorts, including 40 TB positive (16 HIV co-infected), 20 TB negative/HIV negative patients and 5 healthy volunteers. Forty samples were true positives (HIV positive, n = 16), 23 true negatives (HIV negative) and 2 false positives (HIV negative). The McNemar test demonstrated a 3.08% accuracy estimate (CI: -2.1% - 3.08%). This confirms that MTP is expressed during infection, including HIV-TB co-infection, is likely to be suitable for the design of a POC test and supports the validation of MTP for TB detection in larger patient populations.

Indexed as

Antibodies, BacterialAntigens, BacterialCase-Control StudiesFimbriae, BacterialHumansImmunoassayImmunoglobulin GMycobacterium tuberculosisPeptide FragmentsPredictive Value of TestsReproducibility of ResultsTuberculosis, PulmonaryAntibodies, BacterialAntigens, BacterialImmunoglobulin GPeptide FragmentsBiomarkersCurli piliMTBMTPM. tuberculosisTuberculosis

Identifiers

PMID29559125
PMCPMC6477539
OpenAlexW2790072879

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.